Welcome To Achilles Therapeutics

Achilles Therapeutics is a biopharmaceutical company developing personalised T cell therapies targeting neoantigens: protein markers unique to each individual that are present on the surface of a cancer cell and can be detected by the immune system. Our approach is based on the science of tumour evolution which allows us to identify neoantigens that arise early in the cancer’s development and are retained as each tumour grows. These ‘clonal’ neoantigens are present on all the cancer cells and are completely absent from a patient’s healthy tissue. By directing T cells therapies to clonal neoantigens we can for the first time target every cancer cell without attacking healthy tissue.

About Us+

Latest News

Achilles Therapeutics doses first patient in Phase I/II Study in advanced non-small cell lung cancer

23/06/2020

Stevenage, UK 23 June 2020 – Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that…

Read More +

Achilles Therapeutics doses first patient in Phase I/II Study in recurrent or metastatic malignant melanoma with first TIL therapy to specifically target clonal neoantigens

29/05/2020

Stevenage, UK 29 May 2020 – Achilles Therapeutics (“Achilles”), a clinical stage biopharmaceutical company developing personalised cancer immunotherapies, today announced that…

Read More +

Achilles Therapeutics to present at Jefferies Virtual Healthcare Conference

28/05/2020

Stevenage, UK 28 May, 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel…

Read More +

Achilles Therapeutics announces formation of Scientific Advisory Board

13/05/2020

– World-leading experts in oncology, immunology and R&D will advise the Company as it advances pipeline of pioneering cancer therapies –…

Read More +

Achilles Therapeutics to present a manufacturing update at the virtual 2020 AACR Annual Meeting

22/04/2020

Stevenage, UK 22 April, 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel…

Read More +

Achilles Therapeutics appoints Carsten Boess to the Board of Directors

07/04/2020

Stevenage, UK 7 April, 2020 – Achilles Therapeutics (“Achilles”), a clinical-stage oncology company developing personalised cell therapies targeting clonal neoantigens, a novel…

Read More +

Achilles Therapeutics appoints Professor Sergio Quezada as Chief Scientific Officer

17/03/2020

– Professor Quezada is an internationally recognized leader in the field of cancer immunology and a founder of the company –…

Read More +

Achilles Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

07/01/2020

Stevenage, UK 7 January 2020 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announced that Dr. Iraj…

Read More +

Achilles Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

28/11/2019

Stevenage, UK 28 November 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announced that Dr. Iraj Ali,…

Read More +

Achilles Therapeutics to Present at the Jefferies 2019 London Healthcare Conference

14/11/2019

Stevenage, UK 14 November 2019 – Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announced that Dr. Iraj…

Read More +

The Science

Achilles was founded by world-leading experts in cancer evolution, bioinformatics and the development of cell-based immunotherapies. The company brings together these disciplines to develop next-generation, patient-specific cell therapies that harness the immune system to destroy cancer cells.

PROFESSOR CHARLIE SWANTON

Co-founder Charlie Swanton speaks about his career, the advent of immunotherapy and what the Achilles team are looking to achieve.

THE ACHILLES FOUNDERS

Iraj Ali, Charlie Swanton and Karl Peggs discuss the dosing of the first melanoma patient with a cell therapy to specifically target all cancer cells.  This marks a significant milestone for Achilles, delivering the first precision TIL therapy.